Information for medical professionals only.
Internet Drug Information Service Certificate Number: (Lu)-non-commercial-2018-0066
Kexing Biopharm Wins Two Golden Bull Awards for Listed Companies
Release date:2021 - 12 - 20
On December 20, the list of winners of the 23rd (2020) Golden Bull Award for Listed Companies, hosted by China Securities Journal, was officially released. Kexing Biopharm claimed two awards, the 2020 Golden Bull Science and Technology Innovation Award and the 2020 Golden Bull Enterprise Leadership Award.
We are an innovative biopharmaceutical enterprise mainly engaged in the R&D, production, and sales of recombinant protein therapeutics and microecologics. We focus on pharmaceutical research in the fields of antiviral drugs, oncology and immunology, hematology, digestion, and degenerative disease. We are currently committed to the research and development of new proteins, new antibodies, and nucleic acid drugs, which will benefit patients all over the world and help us turn into a leader in high-quality biologicals.
On our journey from public listing to winning the Golden Bull Science and Technology Innovation Award, we have always adhered to the spirit of science and technology innovation.
Year by year, we have increased our R&D investment, with a year-on-year increase of 78.54% for the first three quarters of 2021. Meanwhile, we have recruited a number of top researchers to optimize the composition of our talents, achieving a 53.33% year-on-year increase in the number of researchers holding at least a master's degree. We have established a complete system of pharmaceutical R&D and innovation, covering the whole chain from pharmaceutical discovery to pharmaceutical research, preclinical research, clinical research, and finally, industrialized production. With our three major technical systems (prokaryotic cell technology, eukaryotic cell technology, and viable bacteria technology) and five world-leading technology platforms, we have obtained 39 patents, with nine biopharmaceuticals currently under research, including three new biopharmaceuticals. Our core products remained at the forefront of the industry in China and have been adopted by over 18,000 sales terminals, including over 6500 hospitals across China. It has also been approved and sold in over 30 countries, including Brazil, the Philippines, and Indonesia.
In this year's Golden Bull Award for Listed Companies, Deng Xueqin, Chairman of Kexing Biopharm, won the Golden Bull Enterprise Leadership Award. The Golden Bull Enterprise Leadership Award is given to an enterprise leader with a great pursuit for value, outstanding accomplishments, and excellent leadership skills, who can lead his/her enterprise to great achievements in a complex environment and enjoys a high reputation in the industry.
Ever since he first launched his business, Chairman Deng has been pursuing the spirit of "science and technology innovation", with a strong belief that it is our primary productive force. Therefore, after listing on the Sci-Tech Innovation Board, we have further enhanced the awareness of scientific and technological innovation under his leadership. Looking forward, we will continue to conquer refractory diseases and protect human health, insisting on technological innovation and focusing on unmet clinical needs.
The Golden Bull Award is a financial brand built by the China Securities Journal and the most influential award in China's capital market. Since the China Securities Journal launched its selection of "China's Top 50 Listed Companies with the Greatest Development Potential" in July 1999, the Golden Bull Award for Listed Companies has now concluded its 23rd session. During this time, it has witnessed the development of the capital market, recorded the extraordinary performance of many listed companies in the securities market, and selected several outstanding listed companies under standard governance with growing economic performance and active returns to its shareholders and the society.
Share to:
Scan Code Consultation